Cipla Q1FY27 Revenue Up 2.3% YoY

One India business (Rx + Gx + CHL) achieved its highest-ever quarterly revenue of ₹3,452 Cr, a 12% year-on-year (YoY) growth.
Cipla maintained its #2 rank in the overall Indian chronic therapy market, with the chronic mix improving to 60.4% (IQVIA MAT June'26).
In North America, the company launched its first AB-rated gVentolin inhaler and supplied over 50 million+ inhaler units cumulatively to the U.S. market.
gProventil ranked No. 1 in the overall U.S. Albuterol MDI market with a 21% share (IQVIA week ending 26th June'26).
One Africa business reported revenue of $103 Mn, a 1% YoY growth, with the South Africa private business growing faster than the market.
The South Africa private business revenue was ZAR 906 Mn for Q1FY27.
The company had 10 brands with MAT market revenue greater than 100 Mn ZAR in South Africa.
Key drivers included new product launches like Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash in India, and strong performance in chronic therapies.

One India (Rx + Gx + CHL): Revenue: ₹3,452 Cr; Growth: 12% YoY.
North America: Revenue: $162 Mn.
One Africa (South Africa, North Africa, SSA, CGA): Revenue: $103 Mn; Growth: 1% YoY.
Emerging Markets & Europe: Revenue: $106 Mn; Growth: 5% YoY.
Explanation of significant changes: Growth in the One India segment was driven by double-digit growth in chronic therapies like Respiratory, Urology, Anti-diabetes, and Cardiac.

Revenue: ₹7,119 Cr (Q1FY26: ₹6,957 Cr).
EBITDA: ₹1,192 Cr (Q1FY26: ₹1,778 Cr).
EBITDA Margin: 16.7% (Q1FY26: 25.6%).
PAT: ₹789 Cr (Q1FY26: ₹1,298 Cr).
PAT Margin: 11.1% (Q1FY26: 18.7%).
R&D Expenditure: ₹486 Cr, representing 6.8% of revenue.
YoY comparison: Revenue increased 2.3% YoY, but EBITDA and PAT declined significantly due to higher material and employee costs.
Drivers of financial performance: Higher material cost (₹2,667 Cr vs. ₹2,171 Cr in Q1FY26) and employee benefits expense (₹1,497 Cr vs. ₹1,312 Cr in Q1FY26).
Key Risks: Not explicitly disclosed in the presentation.

Domestic vs Export/Regional Revenue breakdown by value was not provided in the presentation. Revenue was presented by business geography:
One India: ₹3,452 Cr.
North America: $162 Mn.
One Africa: $103 Mn.
Emerging Markets & Europe: $106 Mn.

Total Debt: ₹600 Cr (includes lease liabilities and borrowings).
Cash and Cash Equivalents: ₹10,094 Cr (includes current investments, fixed deposits, margin deposits).
Inventory: ₹6,714 Cr.
Trade Receivables: ₹5,948 Cr.
Trade Payables: ₹3,446 Cr.
Net Tangible Assets: ₹7,889 Cr.
Goodwill and Intangibles: ₹6,928 Cr.
Financial Health Insights: Strong liquidity position with high cash reserves.

Investments in Innovation: Launch of first AB-rated gVentolin inhaler in the U.S.; Ongoing pilot project for building capacity infrastructure for green propellants used in MDIs.
ANDA & NDA Portfolio & Pipeline: Details as on 30th June 2026 were presented but specific numbers were not listed in the provided text.

Renewable Electricity Share: 57% for India manufacturing (Goal: 80% by FY2030).
GHG Emissions (Scope 1 & 2): 21% absolute reduction from FY2024 baseline for Global Cipla (Goal: 30% reduction).
Water Neutrality: Goal is water neutrality for India manufacturing; progress not specified.
Zero Waste to Landfill: CMM Certified in July'26; India Manufacturing Certification targeted for Mar'27.
AMR (Antimicrobial Resistance): Certification for 2 sites targeted for Mar'27.
Occupational Health and Safety: Zero fatalities in manufacturing operations.
DEI (Diversity, Equity, Inclusion): Representation of women in Cipla Leadership Group at 14.8% (Goal: 20% or above from a baseline year of FY25).
Responsible Procurement: Preparation of supplier assessment ESG framework underway (Goal: 80% of critical Indian suppliers to comply).
CIPLA MEDPRO MANUFACTURING PTY LTD, South Africa achieved the Green Building Council certification.